Amicus Therapeutics, Inc.
FOLDNASDAQHealthcare
$14.49
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$14.5
52W Low$5.51
Amicus Therapeutics, Inc.（FOLD）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · FOLD · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.29B | $0.25B | $0.29B | $0.29B | $0.48B |
| Net Receivables | $0.12B | $0.10B | $0.09B | $0.07B | $0.05B |
| Inventory | $0.23B | $0.12B | $0.06B | $0.02B | $0.03B |
| Total Current Assets | $0.68B | $0.50B | $0.48B | $0.42B | $0.60B |
| PP&E Net | $0.05B | $0.05B | $0.06B | $0.06B | $0.06B |
| Goodwill | $0.20B | $0.20B | $0.20B | $0.20B | $0.20B |
| Intangible Assets | $0.01B | $0.02B | $0.02B | $0.02B | $0.02B |
| Total Assets | $0.95B | $0.79B | $0.78B | $0.72B | $0.91B |
| Liabilities | |||||
| Short-Term Debt | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.03B | $0.01B | $0.02B | $0.02B | $0.02B |
| Total Current Liabilities | $0.24B | $0.15B | $0.17B | $0.14B | $0.15B |
| Long-Term Debt | $0.43B | $0.39B | $0.39B | $0.39B | $0.39B |
| Total Liabilities | $0.68B | $0.59B | $0.62B | $0.60B | $0.60B |
| Stockholders Equity | |||||
| Retained Earnings | ($2.77B) | ($2.74B) | ($2.68B) | ($2.53B) | ($2.30B) |
| Total Stockholders Equity | $0.27B | $0.19B | $0.16B | $0.12B | $0.31B |
| Total Liab & Equity(computed) | $0.95B | $0.79B | $0.78B | $0.72B | $0.91B |
| Debt Summary | |||||
| Total Debt | $0.48B | $0.44B | $0.45B | $0.45B | $0.44B |
| Net Debt | $0.27B | $0.23B | $0.20B | $0.30B | $0.19B |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Amicus Therapeutics, Inc.
关于Amicus Therapeutics, Inc.（FOLD）资产负债表
Amicus Therapeutics, Inc.总资产$0.95B，现金及短期投资$0.29B，总负债$0.68B，总债务$0.48B，股东权益$0.27B。
常见问题
FOLD · 4 问Amicus Therapeutics, Inc.总债务$0.48B，净债务$0.27B。
FOLD total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10